Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells.

Recent studies have shown that a number of microRNAs (miRNA or miR) may regulate human breast cancer resistance protein (BCRP/ABCG2), an important efflux transporter responsible for cellular drug disposition, whereas their effects on ABCG2 protein expression are not compared. In this study, we first identified a new proximal miRNA response element (MRE) for hsa-miR-519c within ABCG2 3'-untranslated region (3'UTR) through computational analyses. This miR-519c MRE site was confirmed using dual luciferase reporter assay and site-directed mutagenesis. Immunoblot analyses indicated that ABCG2 protein expression was significantly down-regulated in MCF-7/MX100 cells after transfection with hsa-miR-328- or -519c expression plasmids, and was markedly up-regulated in MCF-7 cells after transfection with miR-328 or -519c antagomir. However, ABCG2 protein expression was unchanged in MCF-7/MX100 cells after transfection with hsa-miR-520h expression plasmids, which was associated with undetectable miR-520h expression. Furthermore, ABCG2 mRNA degradation was accelerated dramatically in cells transfected with miR-519c expression plasmid, suggesting the involvement of mRNA degradation mechanism. Intervention of miR-328 or -519c signaling led to significant change in intracellular mitoxantrone accumulation, as determined by flow cytometry analyses. In addition, we separated RB143 human retinoblastoma cells into stem-like (ABCG2+) and non-stem-like (ABCG2-) populations through immunomagnetic selection, and found that miR-328, -519c and -520h levels were 9-, 15- and 3-fold lower in the ABCG2+ cells, respectively. Our data suggest that miR-519c and -328 have greater impact on ABCG2 expression than miR-520h in MCF-7 human breast cancer cells, and the presence of proximal miR-519c MRE explains the action of miR-519c on shortened ABCG2 3'UTR.

[1]  Caterina A M La Porta,et al.  Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. , 2007, European journal of cancer.

[2]  Guangcun Huang,et al.  Over‐expressed microRNA‐27a and 27b influence fat accumulation and cell proliferation during rat hepatic stellate cell activation , 2009, FEBS letters.

[3]  Shaoxiang Zhang,et al.  MicroRNAs play a role in the development of human hematopoietic stem cells , 2008, Journal of cellular biochemistry.

[4]  Shingo Takagi,et al.  MicroRNAs Regulate Human Hepatocyte Nuclear Factor 4α, Modulating the Expression of Metabolic Enzymes and Cell Cycle* , 2009, The Journal of Biological Chemistry.

[5]  T. Fojo,et al.  Amplification of 4q21–q22 and the MXR gene in independently derived mitoxantrone‐resistant cell lines , 2000, Genes, chromosomes & cancer.

[6]  K. Livak,et al.  Real-time quantification of microRNAs by stem–loop RT–PCR , 2005, Nucleic acids research.

[7]  A. Hackam,et al.  Human embryonic and neuronal stem cell markers in retinoblastoma , 2007, Molecular vision.

[8]  D. Bartel.  MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[9]  Rita Padányi,et al.  High level functional expression of the ABCG2 multidrug transporter in undifferentiated human embryonic stem cells. , 2008, Biochimica et biophysica acta.

[10]  Xiuping Liu,et al.  Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. , 2008, Biochemical pharmacology.

[11]  Shingo Takagi,et al.  MicroRNA regulates the expression of human cytochrome P450 1B1. , 2006, Cancer research.

[12]  Yvonne Tay,et al.  A Pattern-Based Method for the Identification of MicroRNA Binding Sites and Their Corresponding Heteroduplexes , 2006, Cell.

[13]  P. Sharp,et al.  Proliferating Cells Express mRNAs with Shortened 3' Untranslated Regions and Fewer MicroRNA Target Sites , 2008, Science.

[14]  A. Yu.  Role of microRNAs in the regulation of drug metabolism and disposition , 2009, Expert opinion on drug metabolism & toxicology.

[15]  C. Mayr,et al.  Widespread Shortening of 3′UTRs by Alternative Cleavage and Polyadenylation Activates Oncogenes in Cancer Cells , 2009, Cell.

[16]  Marilyn E Morris,et al.  MicroRNA-328 Negatively Regulates the Expression of Breast Cancer Resistance Protein (BCRP/ABCG2) in Human Cancer Cells , 2009, Molecular Pharmacology.

[17]  Shingo Takagi,et al.  Post-transcriptional Regulation of Human Pregnane X Receptor by Micro-RNA Affects the Expression of Cytochrome P450 3A4* , 2008, Journal of Biological Chemistry.

[18]  Y. Miao,et al.  hsa-miR-520h downregulates ABCG2 in pancreatic cancer cells to inhibit migration, invasion, and side populations , 2010, British Journal of Cancer.

[19]  M Dietel,et al.  Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. , 1999, Journal of the National Cancer Institute.

[20]  C. Burge,et al.  Most mammalian mRNAs are conserved targets of microRNAs. , 2008, Genome research.

[21]  Michael Kertesz,et al.  The role of site accessibility in microRNA target recognition , 2007, Nature Genetics.

[22]  M. Morris,et al.  EFFECTS OF DIHYDROPYRIDINES AND PYRIDINES ON MULTIDRUG RESISTANCE MEDIATED BY BREAST CANCER RESISTANCE PROTEIN: IN VITRO AND IN VIVO STUDIES , 2005, Drug Metabolism and Disposition.

[23]  S. Choudhuri,et al.  Molecular targets of epigenetic regulation and effectors of environmental influences. , 2010, Toxicology and applied pharmacology.

[24]  Yuzhuo Pan,et al.  MicroRNAs Regulate CYP3A4 Expression via Direct and Indirect Targeting The online version of this article (available at http://dmd.aspetjournals.org) contains supplemental material. , 2009, Drug Metabolism and Disposition.

[25]  T. Litman,et al.  A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). , 2001, Biochimica et biophysica acta.

[26]  H. Nakauchi,et al.  The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype , 2001, Nature Medicine.

[27]  A. Yu.  Small interfering RNA in drug metabolism and transport. , 2007, Current drug metabolism.

[28]  Olga Kovalchuk,et al.  Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin , 2008, Molecular Cancer Therapeutics.

[29]  M. Dean,et al.  The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[31]  Magnus Ingelman-Sundberg,et al.  Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. , 2007, Pharmacology & therapeutics.

[32]  Thomas Ried,et al.  Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2 , 2009, Molecular Cancer Therapeutics.

[33]  Stijn van Dongen,et al.  miRBase: microRNA sequences, targets and gene nomenclature , 2005, Nucleic Acids Res..

[34]  J. Schuetz,et al.  Role of ABCG2/BCRP in biology and medicine. , 2006, Annual review of pharmacology and toxicology.

[35]  B. Torok-Storb,et al.  The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. , 2002, Blood.

[36]  T. Litman,et al.  Regulation of ABCG2 Expression at the 3′ Untranslated Region of Its mRNA through Modulation of Transcript Stability and Protein Translation by a Putative MicroRNA in the S1 Colon Cancer Cell Line , 2008, Molecular and Cellular Biology.

[37]  Yasuhiro Aoki,et al.  Human CYP2E1 is regulated by miR-378. , 2010, Biochemical pharmacology.

[38]  Fei Li,et al.  Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. , 2002, Cancer research.

[39]  J. Petriz,et al.  Flow cytometry–based approach to ABCG2 function suggests that the transporter differentially handles the influx and efflux of drugs , 2004, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[40]  Yifeng Bai,et al.  Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis. , 2010, European journal of cancer.

[41]  I. T. Young.  Proof without prejudice: use of the Kolmogorov-Smirnov test for the analysis of histograms from flow systems and other sources. , 1977, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[42]  M. Ingelman-Sundberg,et al.  Epigenetic and microRNA-dependent control of cytochrome P450 expression: a gap between DNA and protein. , 2009, Pharmacogenomics.

[43]  G. Merino,et al.  Natural Allelic Variants of Bovine ATP-Binding Cassette Transporter ABCG2: Increased Activity of the Ser581 Variant and Development of Tools for the Discovery of New ABCG2 Inhibitors , 2009, Drug Metabolism and Disposition.

[44]  C. Burge,et al.  Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets , 2005, Cell.

[45]  A. V. van Herwaarden,et al.  The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins. , 2006, Trends in pharmacological sciences.

[46]  V. Ambros.  The functions of animal microRNAs , 2004, Nature.

[47]  Hyunsuk Shim,et al.  Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. , 2010, Biochemical pharmacology.